Active substance
Selenium sulfide
- SFDA 1
- US FDA 7
- US price lines 2
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| SELSUN SHAMPOO | 2.5 % | Shampoo · Topical | 1 Bottle | SAR 11.20 | NCE · OTC | Abbott Laboratories | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| SELENIUM SULFIDE | 2.5% | lotion/shampoo · topical | PADAGIS US | Prescription | 10 Jan 1991 |
| SELSUN | 2.5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | lotion/shampoo · topical | CHATTEM | Discontinued | 17 May 1951 |
| EXSEL | 2.5% | lotion/shampoo · topical | ALLERGAN HERBERT | Discontinued | 21 Jan 1974 |
| SELENIUM SULFIDE | 2.5% | lotion/shampoo · topical | ACTAVIS MID ATLANTIC | Discontinued | 14 May 1975 |
| SELENIUM SULFIDE | 2.5% | lotion/shampoo · topical | IVAX PHARMS | Discontinued | 3 Jul 1980 |
| SELENIUM SULFIDE | 2.5% | lotion/shampoo · topical | COSETTE PHARMS NC | Discontinued | 4 Nov 1981 |
| SELENIUM SULFIDE | 2.5% | lotion/shampoo · topical | PHARMOBEDIENT CNSLTG | Discontinued | 1 Sep 1983 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | SELENIUM SULFIDE 2.25% SHAMPOO | $0.16978 | per ML | 23 Sep 2026 |
| US NADAC | SELENIUM SULFIDE 2.5% LOTION | $0.07813 | per ML | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 13.1. Dermatological medicines > Antifungal medicines · core
Seborrhoeic dermatitis; Pityriasis versicolor
Local > Topical > Suspension: 2% detergent-based
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.